BB
INVA icon

BB Biotech’s Innoviva INVA Stock Holding History

BB Biotech’s Portfolio INVA Stock Details INVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-331,594
Closed -$5.99M – 29
2015
Q2 		$5.99M Sell
331,594
-500,000
-60% -$8.59M 0.16% 28
2015
Q1 		$13.1M Sell
831,594
-211,650
-20% -$3.2M 0.39% 26
2014
Q4 		$14.8M Buy
1,043,244
+300,000
+40% +$4.51M 0.48% 26
2014
Q3 		$12.7M Sell
743,244
-190,000
-20% -$4.36M 0.52% 24
2014
Q2 		$27.8M Sell
933,244
-169,067
-15% -$4.05M 1.32% 17
2014
Q1 		$27.5M Hold
1,102,311
– – 1.42% 17
2013
Q4 		$31.7M Hold
1,102,311
– – 1.69% 13
2013
Q3 		$36.3M Hold
1,102,311
– – 1.98% 14
2013
Q2 		$34.2M Buy
+1,102,311
New +$29.6M 2.47% 12

Other funds holding INVA

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return

BB Biotech's INVA Position: Q3 2015 in Review

BB Biotech sold out of Innoviva (INVA) in Q3 2015, closing a stake of 331,594 shares — an estimated $5.99M sold.

BB Biotech first reported a position in INVA in Q2 2013 and held it in 9 quarters. The position peaked at $36.3M in Q3 2013. 119 funds tracked by Wall St. Rank hold INVA as of Q3 2015.

  • BB Biotech reported no remaining Innoviva position as of Q3 2015 after selling out during the quarter.
  • BB Biotech sold 331,594 Innoviva shares in Q3 2015, an estimated $5.99M.
  • BB Biotech first reported a position in Innoviva in Q2 2013 and held it in 9 quarters.
  • BB Biotech's Innoviva position peaked at $36.3M in Q3 2013.
  • 119 funds tracked by Wall St. Rank held Innoviva as of Q3 2015.

Based on BB Biotech's 13F filing for Q3 2015, filed 12 Nov 2015.